La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Anagenics Gestione

Gestione criteri di controllo 1/4

Anagenics' Il CEO è Karen Matthews, nominato in Jan2024, ha un mandato di meno di un anno. possiede direttamente 0.14% delle azioni della società, per un valore di A$ 4.37K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 2.3 anni.

Informazioni chiave

Karen Matthews

Amministratore delegato

AU$19.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.1%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Dec 17

AMMINISTRATORE DELEGATO

Karen Matthews

less than a year

Mandato

AU$19,168

Compensazione

Ms. Karen Matthews serves as Chief Executive Officer and Director at Anagenics Limited from 2024 and serves as its Non-Executive Director from February 14, 2023. She brings dynamic experience from the Beau...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Karen Matthews	CEO & Director	less than a year	AU$19.17k	0.14% A$ 5.0k
Matthew Dudek	Chief Financial & Governance Officer and Company Secretary	1.3yrs	AU$282.67k	Nessun dato
Scott Greasley	Executive Director	no data	AU$1.15m	0.52% A$ 19.1k
Dominic Burg	Chief Operating Officer	4.1yrs	Nessun dato	Nessun dato
Graham Robertson	Head of Research & Development	no data	Nessun dato	Nessun dato

1.3yrs

Durata media

Gestione esperta: Il team dirigenziale di AN1 non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Karen Matthews	CEO & Director	1.5yrs	AU$19.17k	0.14% A$ 5.0k
Scott Greasley	Executive Director	2.1yrs	AU$1.15m	0.52% A$ 19.1k
Alexander Beard	Non-Executive Chairman	2.5yrs	AU$35.00k	0.94% A$ 34.7k
Phillip Christopher	Non-Executive Director	2.8yrs	AU$26.67k	0.41% A$ 15.0k

2.3yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di AN1 non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

Anagenics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Anagenics Limited, Annual General Meeting, Nov 27, 2023

Anagenics Limited Appoints Karen Matthews as Non-Executive Director

Anagenics Approves the Election of Mr. Alexander Beard as A Director

No independent directors

Anagenics Limited, Annual General Meeting, Nov 29, 2022

Anagenics Limited Announces Resignation of Dennis Eck as Director

Recent updates

Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.32068 million.

Anagenics Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.017 loss in FY 2022)

Anagenics Limited (ASX:AN1) agreed to acquire Face MediGroup for AUD 1.3 million.

New minor risk - Financial data availability

Anagenics Limited Appoints Karen Matthews as Non-Executive Director

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.009 loss in 1H 2022)

Anagenics Limited (ASX:AN1) acquired Uspa Global Pty. Ltd. from BWX Limited (ASX:BWX).

Anagenics Approves the Election of Mr. Alexander Beard as A Director

No independent directors

Anagenics Limited, Annual General Meeting, Nov 29, 2022

Anagenics Limited Announces Resignation of Dennis Eck as Director

Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.027 loss in FY 2021)

Anagenics Limited Appoints Scott Mitchell Greasley as Director

Anagenics Limited Appoints Matthew Dudek as Acting Chief Executive Officer, Effective 28 February 2022

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Anagenics Limited Appoints Mr. Alexander (Sandy) Beard as Director

Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.045 loss in FY 2020)

Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.05 loss in FY 2020)

An unknown buyer signed a binding agreement to acquired Lyramid Limited from Cellmid Limited (ASX:CDY) for AUD 0.5 million

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.016 loss in 1H 2020)

Cellmid Limited Publishes Data on Novel Proprietary FGF5 Aptamer

Cellmid Limited Receives the First Order from Ourui Health Management Limited

Cellmid Limited Announces Executive Changes

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Cellmid Limited, Advangen Limited and Advangen Inc. Signs 10 Year Chinese Distribution Agreement with Ourui Health Management Limited

Cellmid Limited Appoints Sarah Eck-Thompson as Director

Full year earnings released - AU$0.05 loss per share

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media